Biossil is developing an AI-driven drug development platform aimed at finding and reviving pharmaceutical compounds that were previously abandoned in clinical development. The company surfaced from stealth concurrent with its financing announcement. Its stated focus is to use artificial intelligence to reassess and advance failed or shelved drug candidates. Biossil has secured approximately $70 million in equity backing to fund platform development and related activities. Investors named in the financing include OpenAI, Founders Fund, and Staircase Ventures. The article did not disclose operational metrics, revenue, a valuation, or a detailed product roadmap.

Total raised

$70M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2026